BioNTech SE (BNTX) Stock Forecast & Price Target

Compare

4,670 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BNTX Analyst Ratings

Strong Buy

12 Buy

4 Hold

0 Sell

Based on 16 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$134.13

▲(35.13% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $134.13 with a high forecast of $185.00 and a low forecast of $107.00. The average price target represents a 35.13% change from the last price of $99.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"87":"$87","186":"$186","111.75":"$111.8","136.5":"$136.5","161.25":"$161.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$134.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$107.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[87,111.75,136.5,161.25,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.62,107.11076923076924,113.60153846153847,120.0923076923077,126.58307692307693,133.07384615384615,139.5646153846154,146.0553846153846,152.54615384615386,159.03692307692307,165.5276923076923,172.01846153846154,178.50923076923078,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.62,103.19769230769231,105.77538461538462,108.35307692307693,110.93076923076923,113.50846153846155,116.08615384615385,118.66384615384615,121.24153846153845,123.81923076923077,126.39692307692307,128.9746153846154,131.5523076923077,{"y":134.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.62,101.11076923076924,101.60153846153847,102.0923076923077,102.58307692307693,103.07384615384616,103.5646153846154,104.05538461538461,104.54615384615384,105.03692307692307,105.5276923076923,106.01846153846154,106.50923076923077,{"y":107,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$185.00

Average Price Target$134.13

Lowest Price Target$107.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence Flynn

Morgan Stanley

$133

Buy

33.99%

Upside

Reiterated

09/15/25

BioNTech SE (BNTX) Gets a Buy from Morgan Stanley

Tazeen Ahmad

Bank of America Securities

$134

Buy

35.00%

Upside

Reiterated

09/15/25

Bank of America Securities Sticks to Its Buy Rating for BioNTech SE (BNTX)We maintain our Buy with $134 PO.

Geoff Meacham

Citi

$140

Buy

41.04%

Upside

Reiterated

09/11/25

BioNTech SE (BNTX) Receives a Buy from Citi

Evan Seigerman

BMO Capital

$143

Buy

44.07%

Upside

Reiterated

09/09/25

Positive Outlook for BioNTech SE: Stable Vaccine Business and Growth Catalysts Justify Buy Rating

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/09/25

Truist Financial Sticks to Their Buy Rating for BioNTech SE (BNTX)

Daina Graybosch

Leerink Partners

$107

Buy

7.80%

Upside

Reiterated

09/09/25

Analysts Are Bullish on These Healthcare Stocks: McKesson (MCK), BioNTech SE (BNTX)We believe that preliminary global dose optimization outcomes with BioNTech (BNTX, OP) / BMY’s (OP, Risinger) VEGFA/PD-L1 bispecific pumitamig (pumi, BNT327) in combination with chemo in 1L ES-SCLC were exactly that: preliminary. Our enthusiasm remains unchanged—modestly optimistic—until we see a more mature dataset that provides a better look at important duration / survival outcomes key to estimating likelihood of pumi + chemo success in the ongoing, randomized Ph 3 trial, ROSETTA-Lung-01. Albeit in a small sample size, we are encouraged to see that these first global efficacy and promising safety outcomes with pumi in SCLC were largely consistent with those reported from the China-only trial.

Yaron Werber

TD Cowen

$120

Hold

20.89%

Upside

Reiterated

09/08/25

TD Cowen Remains a Hold on BioNTech SE (BNTX)

William Maughan

Clear Street

$185

Buy

86.38%

Upside

Reiterated

09/08/25

BioNTech building integrated oncology pipeline, says Clear StreetBioNTech building integrated oncology pipeline, says Clear Street

Robert Burns

H.C. Wainwright

$136

Buy

37.01%

Upside

Reiterated

09/08/25

BioNTech's Oncology Success and Robust Pipeline Drive Buy Rating

Eliana Merle

UBS

$115

Hold

15.86%

Upside

Reiterated

08/22/25

UBS Remains a Hold on BioNTech SE (BNTX)

Akash Tewari

Jefferies

$151

Buy

52.13%

Upside

Reiterated

08/05/25

Jefferies Remains a Buy on BioNTech SE (BNTX)

Emmanuel Papadakis

Deutsche Bank

$140

Buy

41.04%

Upside

Reiterated

08/05/25

BioNTech SE (BNTX) Receives a Buy from Deutsche Bank

Cory Kasimov

Evercore ISI

$125→$130

Buy

30.97%

Upside

Reiterated

08/04/25

BioNTech SE (BNTX) Gets a Buy from Evercore ISI

Mohit Bansal

Wells Fargo

$170→$150

Buy

51.12%

Upside

Reiterated

08/04/25

BioNTech's Strategic Oncology Focus and Strong Financials Drive Buy Rating

Asad Haider

Goldman Sachs

$110→$112

Hold

12.83%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Ardent Health Partners, Inc. (NYSE: ARDT) and Henry Schein (NASDAQ: HSIC)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence Flynn

Morgan Stanley

$133

Buy

33.99%

Upside

Reiterated

09/15/25

BioNTech SE (BNTX) Gets a Buy from Morgan Stanley

Tazeen Ahmad

Bank of America Securities

$134

Buy

35.00%

Upside

Reiterated

09/15/25

Bank of America Securities Sticks to Its Buy Rating for BioNTech SE (BNTX)We maintain our Buy with $134 PO.

Geoff Meacham

Citi

$140

Buy

41.04%

Upside

Reiterated

09/11/25

BioNTech SE (BNTX) Receives a Buy from Citi

Evan Seigerman

BMO Capital

$143

Buy

44.07%

Upside

Reiterated

09/09/25

Positive Outlook for BioNTech SE: Stable Vaccine Business and Growth Catalysts Justify Buy Rating

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/09/25

Truist Financial Sticks to Their Buy Rating for BioNTech SE (BNTX)

Daina Graybosch

Leerink Partners

$107

Buy

7.80%

Upside

Reiterated

09/09/25

Yaron Werber

TD Cowen

$120

Hold

20.89%

Upside

Reiterated

09/08/25

TD Cowen Remains a Hold on BioNTech SE (BNTX)

William Maughan

Clear Street

$185

Buy

86.38%

Upside

Reiterated

09/08/25

BioNTech building integrated oncology pipeline, says Clear StreetBioNTech building integrated oncology pipeline, says Clear Street

Robert Burns

H.C. Wainwright

$136

Buy

37.01%

Upside

Reiterated

09/08/25

BioNTech's Oncology Success and Robust Pipeline Drive Buy Rating

Eliana Merle

UBS

$115

Hold

15.86%

Upside

Reiterated

08/22/25

UBS Remains a Hold on BioNTech SE (BNTX)

Akash Tewari

Jefferies

$151

Buy

52.13%

Upside

Reiterated

08/05/25

Jefferies Remains a Buy on BioNTech SE (BNTX)

Emmanuel Papadakis

Deutsche Bank

$140

Buy

41.04%

Upside

Reiterated

08/05/25

BioNTech SE (BNTX) Receives a Buy from Deutsche Bank

Cory Kasimov

Evercore ISI

$125→$130

Buy

30.97%

Upside

Reiterated

08/04/25

BioNTech SE (BNTX) Gets a Buy from Evercore ISI

Mohit Bansal

Wells Fargo

$170→$150

Buy

51.12%

Upside

Reiterated

08/04/25

BioNTech's Strategic Oncology Focus and Strong Financials Drive Buy Rating

Asad Haider

Goldman Sachs

$110→$112

Hold

12.83%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Ardent Health Partners, Inc. (NYSE: ARDT) and Henry Schein (NASDAQ: HSIC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

1 Month

xxx

Success Rate

15/28 ratings generated profit

Average Return

+2.30%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.57% of your transactions generating a profit, with an average return of +2.30% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

-0.82%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.82% per trade.

1 Year

Daina GrayboschLeerink Partners

Success Rate

13/26 ratings generated profit

Average Return

+0.51%

reiterated a buy rating 9 days ago

Copying Daina Graybosch's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.51% per trade.

2 Years

xxx

Success Rate

13/25 ratings generated profit

Average Return

-1.30%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.00% of your transactions generating a profit, with an average return of -1.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BNTX has received 27 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 134.13.

Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is -$1.22 with a range of -$2.46 to $0.84. The previous quarter’s EPS was -$1.87. BNTX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $791.87M with a range of $459.20M to $1.14B. The previous quarter’s sales results were $295.83M. BNTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.14% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?

Based on analyst ratings, BioNTech SE’s 12-month average price target is 134.13.

What is BNTX’s upside potential, based on the analysts’ average price target?

BioNTech SE has 35.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BNTX a Buy, Sell or Hold?

BioNTech SE has a consensus rating of Strong Buy which is based on 12 buy ratings, 4 hold ratings and 0 sell ratings.

What is BioNTech SE’s price target?

The average price target for BioNTech SE is 134.13. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $107.00. The average price target represents 35.13% Increase from the current price of $99.26.

What do analysts say about BioNTech SE?

BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of BNTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioNTech SE (BNTX) Stock Forecast & Price Target

BNTX Analyst Ratings

BNTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

BNTX Analyst Recommendation Trends

BNTX Financial Forecast

BNTX Earnings Forecast

BNTX Sales Forecast

BNTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts